IL-36 is a member of the IL-1 superfamily and consists of three agonists and one receptor
antagonist (IL-36Ra). The three endogenous agonists, IL-36α,–β, and–γ, act primarily as …

The triggers and pathogenesis of axial spondyloarthritis (axSpA) are not yet completely
understood. However, therapeutic agents targeting tumor necrosis factor-α and interleukin …

Objective Self-injectable TNF inhibitors are increasingly used early in the chronic treatment
of moderate to severe rheumatologic conditions. We estimated medication adherence …

Inflammatory bowel disease (IBD) is a chronic inflammatory disease primarily affecting the
gastrointestinal (GI) tract and other organs. In this article, we provide a comprehensive …

Background Clinical trial evidence demonstrates the efficacy of tofacitinib in ankylosing
spondylitis and psoriatic arthritis (PsA). Real‐world data from spondyloarthritis (SpA) …

Background: Switching between therapies is a recommended strategy for psoriatic arthritis
(PsA) patients who experience treatment failure; however, studies including real-life data are …

There have been significant advances in the treatment of psoriatic arthritis (PsA). Despite
these advances, racial and ethnic disparities in clinical outcomes may still exist in patients …

Interventions: TwHF with a priming dose of 20 mg 3 times per day and a gradual dose
reduction of 20 mg per day in every 3 months. Four months later, methotrexate was added …

Spondyloarthritis represents a heterogeneous group of articular inflammatory diseases that
share common genetic, clinical and radiological features. Recently, novel insights into the …

Management of Psoriatic Arthritis: Turkish League Against Rheumatism (TLAR) Expert
Opinions - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage …